Clinical Trial Results:
GeparQuattro: A randomized phase III study exploring the efficacy of Capecitabine given concomitantly or in sequence to EC - Doc with or without Trastuzumab as neoadjuvant treatment of primary breast cancer.
A joint study of GBG and AGO
Summary
|
|
EudraCT number |
2005-001546-17 |
Trial protocol |
DE |
Global completion date |
01 Aug 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
09 Sep 2021
|
First version publication date |
09 Sep 2021
|
Other versions |
|
Summary report(s) |
CSR Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.